Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that IDH2 p.R172S status confers therapeutic sensitivity to Vorasidenib in patients with Astrocytoma.
This statement is based on a regulatory approval from the Health Canada:
VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.